Revisão: Coagulopatia associada a COVID-19 e agentes antitrombóticos – Em pacientes internados não críticos, anticoagulação em dose plena com heparina de baixo peso molecular pode melhorar os resultados clínicos. Em pacientes críticos, o mesmo tratamento não traz essa melhora, sendo recomendada a dose profilática

COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year – The Lancet Haematology

Relacionado: Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials E RCT: Intermediate-dose enoxaparin (1 mg/kg/d) not better than standard-dose prophylactic anticoagulation in patients with Covid-19 admitted to the intensive care unit

Comentário no Twitter

🆕💥💥State of the Art Review Article @TheLancetHaem by @MiddeldorpS
COVID-19-associated coagulopathy
Excellent explanation for the pathophysiology and great summary for the major RCTs and clinical guidelines https://t.co/NxP06KP2Hm pic.twitter.com/qHzyDsUZpt

— Antibiotic Steward🆔🦠Bassam Ghanem (@ABsteward) April 28, 2021